Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
AHA26: Semaglutide’s real-world CV benefits highlight importance of persistence
Real-world semaglutide CV outcomes mirror clinical trials, with greater treatment persistence linked to better outcomes.
Read Full Article
Pharma Tech
BIO Europe: Financing, AI and geopolitics shape biotech discourse
Speakers at BIO-Europe 2026 noted that European biotechs must be agile and adaptable in times of geopolitical and financial upheaval.
Read Full Article
PharmaShots
Top 20 Cardiometabolic Prescription Drugs of 2026
Shots: 20. Xultophy Non-Proprietary Name: Insulin degludec/liraglutide Company: Novo Nordisk First Approved: EU (2014), US (2016) FY2025 Revenue: $0.72B FY2024 Revenue: $0.62B YoY Growth: +15.7% 19. Kerendia Non-Proprietary Name: Finerenone Company: Bayer First Approved: US (2021), EU (2022) FY2025 Revenue: $0.97B FY2024 Revenue: $0.48B YoY Growth: +102% 18. Leqvio Non-Proprietary Name: Inclisiran Company: Novartis First Approved: US (2021), EU (2020) FY2025 Revenue: $1.19B FY2024 Revenue: $0.75B YoY Growth: +58.9% 17.… The post Top 20 Cardiometabolic Prescription Drugs of 2026 appeared first on PharmaShots.
Read Full Article
Pharma Tech
FDA puts commissioner’s priority voucher framework on ice
Experts consistently questioned how vouchers were awarded, along with critiquing its wider industry benefits.
Read Full Article
Express Pharma
From volume to value: How India’s pharma industry can move up the global value chain
Arun Patel, Founder and Partner, Arunasset Investment Services, explains how India’s pharma industry can move beyond volume-led growth and strengthen its position in the global value chain The post From volume to value: How India’s pharma industry can move up the global value chain appeared first on Express Pharma.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Nov 14, 2026, 2:27 AM
Bristol Myers to merge scientific, clinical teams under new R&D structure
Current Chief Research Officer Robert Plenge will leave in March 2027 after the transition.
ET Pharma
Nov 14, 2026, 2:25 AM
Breakthrough HIV drug sees 18 patent filings, may delay affordable generics
In a letter to the department for promotion of industry and internal trade, patient groups demanded that the patent office must rigorously examine and reject the company's secondary patent applications.
ET Pharma
Nov 14, 2026, 2:22 AM
Compulsory Licensing of Drugs Only After Exhausting All Other Measures: Pharma secy
The government plans to address the high costs of innovative medicines by first negotiating prices. Compulsory licensing will be considered only after other alternatives are exhausted. Trade margins on high-cost drugs are being examined to enhance affordability. Discussions are ongoing with pharmaceutical companies to improve access and affordability of patented drugs. The government is also working on initiatives to support the local pharmaceutical manufacturing sector.
Pharma Tech
Nov 13, 2026, 4:07 PM
AHA26: Semaglutide’s real-world CV benefits highlight importance of persistence
Real-world semaglutide CV outcomes mirror clinical trials, with greater treatment persistence linked to better outcomes.
Pharma Tech
Nov 13, 2026, 3:36 PM
BIO Europe: Financing, AI and geopolitics shape biotech discourse
Speakers at BIO-Europe 2026 noted that European biotechs must be agile and adaptable in times of geopolitical and financial upheaval.
PharmaShots
Nov 13, 2026, 1:30 PM
Top 20 Cardiometabolic Prescription Drugs of 2026
Shots: 20. Xultophy Non-Proprietary Name: Insulin degludec/liraglutide Company: Novo Nordisk First Approved: EU (2014), US (2016) FY2025 Revenue: $0.72B FY2024 Revenue: $0.62B YoY Growth: +15.7% 19. Kerendia Non-Proprietary Name: Finerenone Company: Bayer First Approved: US (2021), EU (2022) FY2025 Revenue: $0.97B FY2024 Revenue: $0.48B YoY Growth: +102% 18. Leqvio Non-Proprietary Name: Inclisiran Company: Novartis First Approved: US (2021), EU (2020) FY2025 Revenue: $1.19B FY2024 Revenue: $0.75B YoY Growth: +58.9% 17.… The post Top 20 Cardiometabolic Prescription Drugs of 2026 appeared first on PharmaShots.
News
Latest industry coverage
Google News
Nov 14, 2026, 8:04 PM
Better Biotech ETF: First Trust's FBT vs. Invesco's PBE - The Motley Fool
Better Biotech ETF: First Trust's FBT vs. Invesco's PBE The Motley Fool
Google News
Nov 14, 2026, 7:46 PM
Aida Piedra: How Does It Feel to See Drug Development From a New Perspective? - Oncodaily
Aida Piedra: How Does It Feel to See Drug Development From a New Perspective? Oncodaily
Google News
Nov 14, 2026, 5:42 PM
Indian Pharmaceutical Exports Surge 29% in October, Outlook Positive - UPPERNEWS
Indian Pharmaceutical Exports Surge 29% in October, Outlook Positive UPPERNEWS
Google News
Nov 14, 2026, 5:12 PM
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027? - The Motley Fool
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027? The Motley Fool
Google News
Nov 14, 2026, 4:43 PM
A bitter pill: Indian pharma industry, Trump’s tariff and a Congress that campaigned on cheaper care - The Times of India
A bitter pill: Indian pharma industry, Trump’s tariff and a Congress that campaigned on cheaper care The Times of India
Google News
Nov 14, 2026, 4:10 PM
India's pharma industry shifts to high-value drugs, advanced manufacturing to cut China dependence: Report - Business Today
India's pharma industry shifts to high-value drugs, advanced manufacturing to cut China dependence: Report Business Today
Google News
Nov 14, 2026, 3:35 PM
NPPA Orders Strict Monitoring of 30% Trade Margin Cap on 137 Cancer Drugs, Warns of Penal Action - Medical Dialogues
NPPA Orders Strict Monitoring of 30% Trade Margin Cap on 137 Cancer Drugs, Warns of Penal Action Medical Dialogues
Google News
Nov 14, 2026, 3:25 PM
Zydus Lifesciences' UK LiqMeds Facility Gets 4 USFDA Inspection Observations - Medical Dialogues
Zydus Lifesciences' UK LiqMeds Facility Gets 4 USFDA Inspection Observations Medical Dialogues
Google News
Nov 14, 2026, 3:15 PM
Pharma Firm Founder, Wife Face Insolvency Proceedings Over Rs 256.29 Crore Dues - Medical Dialogues
Pharma Firm Founder, Wife Face Insolvency Proceedings Over Rs 256.29 Crore Dues Medical Dialogues
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer